Compare MAX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAX | PLRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.4M | 81.1M |
| IPO Year | 2020 | 2020 |
| Metric | MAX | PLRX |
|---|---|---|
| Price | $10.06 | $1.33 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $12.70 | $2.67 |
| AVG Volume (30 Days) | ★ 440.0K | 409.5K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.81 | ★ 29.97 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $1,113,600,000.00 | N/A |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $25.72 | ★ N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $7.09 | $1.09 |
| 52 Week High | $13.92 | $1.95 |
| Indicator | MAX | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.85 | 57.52 |
| Support Level | $9.95 | $1.12 |
| Resistance Level | $10.59 | $1.44 |
| Average True Range (ATR) | 0.37 | 0.07 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 87.58 | 93.75 |
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.